Targeting the ERBB family in cancer: Couples therapy

Nature Reviews Cancer

Volumn 13, Issue 9, 2013, Pages 663-673

  Tebbutt, Niall ^c   Pedersen, Mikkel W ^b   Johns, Terrance G ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b Symphogen AS   (Denmark)

^c AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; AFATINIB; CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; GEFITINIB; GEMCITABINE; LAPATINIB; MM 151; MONOCLONAL ANTIBODY 528; MONOCLONAL ANTIBODY 806; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; SYM 004; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AUTOPHOSPHORYLATION; BLOOD BRAIN BARRIER; BREAST CANCER; BREAST METASTASIS; CANCER GENE THERAPY; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; COLON CANCER; COLORECTAL CANCER; DIMERIZATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENE TARGETING; GLIOMA; GLUCOSE METABOLISM; GLYCOSYLATION; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IN VITRO STUDY; INTERNALIZATION; LIGAND BINDING; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAGNESIUM BLOOD LEVEL; MAXIMUM TOLERATED DOSE; MITOCHONDRIAL TARGETING SIGNAL; MOLECULAR DOCKING; MONOTHERAPY; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECEPTOR DOWN REGULATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TUMOR XENOGRAFT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84883179862     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3559     Document Type: Review

References (90)

1. Casalini, P., Iorio, M. V., Galmozzi, E. & Menard, S. Role of HER receptors family in development and differentiation. J. Cell. Physiol. 200, 343-350 (2004).
2. Prenzel, N., Fischer, O. M., Streit, S., Hart, S. & Ullrich, A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer 8, 11-31 (2001).
3. Roskoski, R. Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun. 319, 1-11 (2004).
4. Hynes, N. E., Horsch, K., Olayioye, M. A. & Badache, A. The ErbB receptor tyrosine family as signal integrators. Endocr. Relat. Cancer 8, 151-159 (2001).
5. Shi, F., Telesco, S. E., Liu, Y., Radhakrishnan, R. & Lemmon, M. A. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl Acad. Sci. USA 107, 7692-7697 (2010).
6. Zhang, Q., Park, E., Kani, K. & Landgraf, R. Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling. Proc. Natl Acad. Sci. USA 109, 13237-13242 (2012).
7. Yarden, Y. & Pines, G. The ERBB network: at last, cancer therapy meets systems biology. Nature Rev. Cancer 12, 553-563 (2012).
8. Hynes, N. E. & MacDonald, G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 21, 177-184 (2009).
9. Sundvall, M. et al. Role of ErbB4 in breast cancer. J. Mammary Gland Biol. Neoplasia 13, 259-268 (2008).
10. Prickett, T. D. et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nature Genet. 41, 1127-1132 (2009).
11. Albanell, J. & Gascon, P. Small molecules with EGFR-TK inhibitor activity. Curr. Drug Targets 6, 259-274 (2005).
12. Mendelsohn, J. & Baselga, J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 33, 369-385 (2006).
13. Bria, E. et al. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann. Oncol. 22, 2277-2285 (2011).
14. Wheeler, D. L., Dunn, E. F. & Harari, P. M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nature Rev. Clin. Oncol. 7, 493-507 (2010).
15. Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J. & Bardelli, A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl Cancer Inst. 101, 1308-1324 (2009).
16. Schmitz, K. R. & Ferguson, K. M. Interaction of antibodies with ErbB receptor extracellular regions. Exp. Cell Res. 315, 659-670 (2009).
17. Bos, M. et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin. Cancer Res. 3, 2099-2106 (1997).
18. Johns, T. G. et al. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc. Natl Acad. Sci. USA 100, 15871-15876 (2003).
19. Gan, H. K. et al. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806. J. Biol. Chem. 282, 2840-2850 (2007).
20. Perera, R. M. et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin. Cancer Res. 11, 6390-6399 (2005).
21. Matar, P. et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin. Cancer Res. 10, 6487-6501 (2004).
22. Huang, S., Armstrong, E. A., Benavente, S., Chinnaiyan, P. & Harari, P. M. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 64, 5355-5362 (2004).
23. Jimeno, A. et al. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res. 65, 3003-3010 (2005).
24. Scaltriti, M. et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28, 803-814 (2009).
25. Rimawi, M. F. et al. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin. Cancer Res. 17, 1351-1361 (2011).
26. Wainberg, Z. A. et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin. Cancer Res. 16, 1509-1519 (2010).
27. Scheuer, W. et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 69, 9330-9336 (2009).
28. Yamashita-Kashima, Y. et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin. Cancer Res. 17, 5060-5070 (2011).
29. Weickhardt, A. J. et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J. Clin. Oncol. 30, 1505-1512 (2012).
30. Regales, L. et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J. Clin. Invest. 119, 3000-3010 (2009).
31. Huang, P. H. et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl Acad. Sci. USA 104, 12867-12872 (2007).
32. Alvarado, D., Klein, D. E. & Lemmon, M. A. ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor. Nature 461, 287-291 (2009).
33. Huang, S. et al. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res. 73, 824-833 (2013).
34. Yonesaka, K. et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 3, 99ra86 (2011).
35. Garrett, J. T., Sutton, C. R., Kuba, M. G., Cook, R. S. & Arteaga, C. L. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin. Cancer Res. 19, 610-619 (2013).
36. Cavazzoni, A. et al. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines. Mol. Cancer 11, 91 (2012).
37. Bibeau, F. et al. Impact of FcRIIa-FcRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 27, 1122-1129 (2009).
38. Varchetta, S. et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 67, 11991-11999 (2007).
39. Wang, Q. et al. Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res. 72, 4417-4428 (2012).
40. Stagg, J. et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl Acad. Sci. USA 108, 7142-7147 (2011).
41. Spangler, J. B. et al. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc. Natl Acad. Sci. USA 107, 13252-13257 (2010).
42. Schmidt, M. H., Furnari, F. B., Cavenee, W. K. & Bogler, O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc. Natl Acad. Sci. USA 100, 6505-6510 (2003).
43. Pedersen, M. W. et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res. 70, 588-597 (2010).
44. Zhu, H., Cao, X., Ali-Osman, F., Keir, S. & Lo, H. W. EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. Cancer Lett. 294, 101-110 (2010).
45. Weihua, Z. et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13, 385-393 (2008).
46. Xu, S. & Weihua, Z. Loss of EGFR induced autophagy sensitizes hormone refractory prostate cancer cells to adriamycin. Prostate 71, 1216-1224 (2011).
47. Taylor, T. E., Furnari, F. B. & Cavenee, W. K. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr. Cancer Drug Targets 12, 197-209 (2012).
48. Vivanco, I. et al. Differential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2, 458-471 (2012).
49. Hegi, M. E. et al. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib-a phase II trial. Mol. Cancer Ther. 10, 1102-1112 (2011).
50. Gan, H. K., Kaye, A. H. & Luwor, R. B. The EGFRvIII variant in glioblastoma multiforme. J. Clin. Neurosci. 16, 748-754 (2009).
51. Heimberger, A. B. et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin. Cancer Res. 8, 3496-3502 (2002).
52. Oxnard, G. R. et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin. Cancer Res. 17, 5530-5537 (2011).
53. Brand, T. M., Iida, M., Li, C. & Wheeler, D. L. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov. Med. 12, 419-432 (2011).
54. Li, C., Iida, M., Dunn, E. F., Ghia, A. J. & Wheeler, D. L. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28, 3801-3813 (2009).
55. Huang, W. C. et al. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. J. Biol. Chem. 286, 20558-20568 (2011).
56. Cvrljevic, A. N. et al. Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. J. Cell Sci. 124, 2938-2950 (2011).
57. Demory, M. L. et al. Epidermal growth factor receptor translocation to the mitochondria: regulation and effect. J. Biol. Chem. 284, 36592-36604 (2009).
58. Ramalingam, S. et al. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. J. Thorac. Oncol. 3, 258-264 (2008).
59. Baselga, J. et al. A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC). J. Clin. Oncol. Abstr. 24, 3006 (2006).
60. Sangha, R. et al. Dual epidermal growth factor receptor (EGFR) inhibition: phase I study combining cetuximab (C225) and erlotinib (E) in advanced solid tumors. J. Clin. Oncol. Abstr. 27, 3552 (2009).
61. Janjigian, Y. Y. et al. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin. Cancer Res. 17, 2521-2527 (2011).
62. Janjigian, Y. Y. et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J. Clin. Oncol. Abstr. 29, 7525 (2011).
63. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
64. Schaefer, G., Shao, L., Totpal, K. & Akita, R. W. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res. 67, 1228-1238 (2007).
65. Deeken, J. F. et al. A phase I study of lapatinib (LPT) and cetuximab (CTX) in patients with CTX-sensitive solid tumors. J. Clin. Oncol. Abstr. 30, 2590 (2012).
66. Kim, G. P. et al. Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma. J. Clin. Oncol. Abstr. 29, 4030 (2011).
67. Blackwell, K. L. et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab- refractory metastatic breast cancer. J. Clin. Oncol. 28, 1124-1130 (2010).
68. Baselga, J. et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379, 633-640 (2012).
69. Dienstmann, R. et al. Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients with advanced solid tumors. J. Clin. Oncol. Abstr. 29, 3089 (2011).
70. Cobleigh, M. A. et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648 (1999).
71. Gianni, L. et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 12, 236-244 (2011).
72. Smith, I. et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369, 29-36 (2007).
73. Baselga, J. et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 28, 1138-1144 (2010).
74. Baselga, J. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109-119 (2012).
75. Gianni, L. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 25-32 (2012).
76. Spangler, J. B., Manzari, M. T., Rosalia, E. K., Chen, T. F. & Wittrup, K. D. Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. J. Mol. Biol. 422, 532-544 (2012).
77. Schaefer, G. et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20, 472-486 (2011).
78. Dong, J. et al. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol. Cancer Ther. 9, 2593-2604 (2010).
79. Vincenzi, B., Zoccoli, A., Pantano, F., Venditti, O. & Galluzzo, S. Cetuximab: from bench to bedside. Curr. Cancer Drug Targets 10, 80-95 (2010).
80. Schneider-Merck, T. et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J. Immunol. 184, 512-520 (2010).
81. Garrett, T. P. et al. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc. Natl Acad. Sci. USA 106, 5082-5087 (2009).
82. Johns, T. G. et al. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J. Biol. Chem. 279, 30375-30384 (2004).
83. Yoshida, T., Zhang, G. & Haura, E. B. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Biochem. Pharmacol. 80, 613-623 (2010).
84. Linardou, H., Dahabreh, I. J., Bafaloukos, D., Kosmidis, P. & Murray, S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nature Rev. Clin. Oncol. 6, 352-366 (2009).
85. Boschelli, D. H. 4-anilino-3-quinolinecarbonitriles: an emerging class of kinase inhibitors. Curr. Top. Med. Chem. 2, 1051-1063 (2002).
86. Hudis, C. A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51 (2007).
87. Reid, A., Vidal, L., Shaw, H. & de Bono, J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur. J. Cancer 43, 481-489 (2007).
88. Xia, W. et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21, 6255-6263 (2002).
89. Li, D. et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27, 4702-4711 (2008).
90. Spicer, J. F. & Rudman, S. M. EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Target Oncol. 5, 245-255 (2010).